ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-03-03 23:52:12 ET
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST
Company Participants
Patrick Soon-Shiong - Founder, Executive Chairman and Global Chief Scientific & Medical Officer
Richard Adcock - President, CEO & Director
...
Read the full article on Seeking Alpha
For further details see:
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio Inc.
NASDAQ: IBRX
IBRX Trading
-0.29% G/L:
$8.875 Last:
12,794,005 Volume:
$8.78 Open:
IBRX Latest News
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
February 27, 2026 07:30:00 am
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
February 26, 2026 07:30:00 am
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
February 25, 2026 09:00:00 am
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
IBRX Stock Data
$6,497,322,803
300,611,373
0.32%
122
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
